Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 3022.

https://doi.org/10.1182/blood.V118.21.3022.3022

Published: 2011

Journal Articles

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Rachid Baz, MD, Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth Shain, MD, PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Jose Leonel Ochoa-Bayona, M.D., Daniel Sullivan, MD, Benjamin Djulbegovic, MD, PhD, William S. Dalton, PhD, MD

Blood (2011) 118 (21): 1878.

https://doi.org/10.1182/blood.V118.21.1878.1878

Published: 2011

Journal Articles

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jose-Leonel ochoa-Bayona, M.D., Melissa Alsina, MD, Ernesto Ayala, MD, Jongphil Kim, Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 2381.

https://doi.org/10.1182/blood.V116.21.2381.2381

Published: 2010

Journal Articles

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Jongphil Kim, Ernesto Ayala, MD, Melissa Alsina, MD, Jose-Leonel ochoa-Bayona, M.D., Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 1333.

https://doi.org/10.1182/blood.V116.21.1333.1333

Published: 2010

Journal Articles

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Elizabeth Finley-Oliver, RN, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jose-Leonel Ochoa-Bayona, M.D., Melissa Alsina, MD, Daniel Sullivan, MD, William S. Dalton, PhD, MD, Rachid Baz, MD

Blood (2010) 116 (21): 4756.

https://doi.org/10.1182/blood.V116.21.4756.4756

Published: 2010

Journal Articles

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Rachid Baz, MD, Mohamad A Hussein, MD, Daniel Sullivan, MD, Jose-Leonel Ochoa-Bayona, M.D., Monique A Hartley, MD, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jennifer Paleveda, Kara Kosakowski, William S. Dalton, PhD, MD, Melissa Alsina, MD

Blood (2010) 116 (21): 3054.

https://doi.org/10.1182/blood.V116.21.3054.3054

Published: 2010

NARROW

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only